Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice.

× No keyword cloud information.

17 in total

Review 1. Resistance to TRAIL and how to surmount it.

Authors: Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal: Immunol Res Date: 2012-04 Impact factor: 2.829

2. TRAIL receptor deficiency sensitizes mice to dextran sodium sulphate-induced colitis and colitis-associated carcinogenesis.

Authors: Jieqing Zhu; Longfei Chen; Juan Shi; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal: Immunology Date: 2014-02 Impact factor: 7.397

3. Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis.

Authors: Emilie T E Gross; Semi Han; Prasantha Vemu; Carlos D Peinado; Martin Marsala; Lesley G Ellies; Jack D Bui
Journal: Oncoimmunology Date: 2016-12-14 Impact factor: 8.110

Review 4. The therapeutic potential of TRAIL receptor signalling in cancer cells.

Authors: R Yerbes; C Palacios; A López-Rivas
Journal: Clin Transl Oncol Date: 2011-12 Impact factor: 3.405

5. The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.

Authors: Brett D Shepard; Andrew D Badley
Journal: Antiinfect Agents Med Chem Date: 2009-04-01

Review 6. Immune surveillance of tumors.

Authors: Jeremy B Swann; Mark J Smyth
Journal: J Clin Invest Date: 2007-05 Impact factor: 14.808

Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice.

Review 1. Resistance to TRAIL and how to surmount it.

2. TRAIL receptor deficiency sensitizes mice to dextran sodium sulphate-induced colitis and colitis-associated carcinogenesis.

3. Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis.

Review 4. The therapeutic potential of TRAIL receptor signalling in cancer cells.

5. The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.

Review 6. Immune surveillance of tumors.

Review 7. Caspase inhibitors for the treatment of hepatitis C.

8. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.

9. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development.

Review 10. Targeting apoptosis in autoimmune hepatitis.